对发作的二线治疗方法的比较有效性
Kristen Barbour1, Shaun A Hussain2, Kelly G Knupp3
1University of California, San Diego, La Jolla, California, USA.
Epilepsia
|June 18, 2025
概括
婴儿发作综合征 (IESS) 的第二次治疗显示缓解率较低. 切换药物类型,如激素疗法到vigabatrin或相反,为患有IESS的婴儿提供了缓解的最佳机会.
科学领域:
- 儿科神经学 儿科神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 临床药理学 临床药理学
背景情况:
- 婴儿发作综合征 (IESS) 是婴儿的一种严重综合征.
- 对初始疗法的治疗反应可能是可变的,需要对二线治疗策略进行评估.
- 了解不同第二次治疗序列的疗效对于优化患者的治疗结果至关重要.
研究的目的:
- 评估婴儿发作综合征 (IESS) 的各种第二次治疗方案的有效性.
- 在IESS的婴儿中比较标准和非标准疗法的不同序列之间的缓解率.
- 根据临床反应确定IESS的最佳二线治疗策略.
主要方法:
- 预计将在21个美国儿科中心 (2012-2018) 招收153名婴儿 (2-24个月) 接受IESS治疗.
- 对接受标准一线治疗 (荷尔蒙疗法或vigabatrin) 随后接受第二次治疗的婴儿进行分析,但不包括结核性硬化症的婴儿.
- 使用二进制逻辑回归,在治疗组 (荷尔蒙到维加巴特林,荷尔蒙到荷尔蒙,荷尔蒙到非标准,维加巴特林到荷尔蒙,维加巴特林到非标准) 中比较3个月临床缓解率.
主要成果:
- 最高的3个月缓解率在激素治疗对维加巴特林 (34%) 和维加巴特林对激素治疗 (35%) 组中观察到.
- 激素治疗与非标准治疗的缓解率显着较低 (3.3%),与对维加巴林基准组的激素治疗相比 (OR = .07).
- 在荷尔蒙治疗与荷尔蒙治疗组 (18%) 之间,与对维格巴特林 (OR = .43) 的荷尔蒙治疗相比,观察到较低缓解的趋势.
结论:
- 对IESS第二次治疗的整体反应率仍然很低,最多三分之一的婴儿实现了缓解.
- 切换第二次治疗的作用机制 (例如,从激素疗法转变为维加巴或反之亦然) 是一种支持的临床策略.
- 该研究加强了对标准疗法的偏好,而不是非标准的选择,作为IESS的二线治疗.
相关概念视频
Spasmolytic Agents: Chemical Classification
1.0K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.0K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.7K
Antiepileptic Drugs: Glutamate Antagonists
528
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
528
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
463
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
463
Classification of Skeletal Muscle Relaxants
2.7K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.7K
Centrally Acting Muscle Relaxants: Therapeutic Uses
877
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
877


